OBX

Today, 9:15 AMObsidian's amsoki-cel shows 67% objective response rate with durable responses, favorable safety in Phase 1/2 immune-checkpoint inhibitor–resistant advanced melanoma

Peers: IOVA IMTX LYEL ARTV LEGN REPL TIL TCRX NKTX ACET

| Held by: VTI VXF SCHA ITOT SCHB ONEQ TNXT

Scroll to Statements

Index	-
Market Cap	846.29M
Enterprise Value	1.14B
Income	124.25M
Sales	0.00M
Book/sh	-2701.52
Cash/sh	0.56
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	3
IPO	Nov 07, 2019

P/E	0.08
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	24.57
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.30
Current Ratio	2.30
Debt/Eq	0.10
LT Debt/Eq	0.03
Option/Short	No / Yes

EPS (ttm)	161.87
EPS next Y	-
EPS next Q	-0.52
EPS this Y	-
EPS next Y	-
EPS next 5Y	79.31%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	469.96%
Sales Y/Y TTM	-
EPS Q/Q	-10780.55%
Sales Q/Q	-
Earnings	Aug 12
EPS/Sales Surpr.	-4.89% -

Insider Own	12.40%
Insider Trans	0.00%
Inst Own	21.65%
Inst Trans	19.11%
ROA	432.24%
ROE	-
ROIC	397.65%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	4.59%
SMA50	-6.62%
SMA200	-5.24%
Trades

Shs Outstand	61.77M
Shs Float	54.11M
Short Float	2.00%
Short Ratio	2.58
Short Interest	1.08M
52W High	49.97 -72.58%
52W Low	4.00 242.50%
Volatility	16.69% 10.72%
ATR (14)	1.75
RSI (14)	50.43
Beta	3.20
Rel Volume	4.31
Avg Volume	418.42K
Volume	1,491,222

Perf Week	-7.37%
Perf Month	11.93%
Perf Quarter	-60.86%
Perf Half Y	-31.50%
Perf YTD	211.36%
Perf Year	197.83%
Perf 3Y	-53.59%
Perf 5Y	-96.39%
Perf 10Y	-
Recom	1.00
Target Price	39.00
Prev Close	9.60
Price	13.70
Change %	42.71%

Consensus

Strong Buy

Avg. Price Target

$39.00

Implied Upside

+184.7%

Analysts4incl. previous ratings

Rating Distribution4 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 22, 2026	Initiated	LLeerink Partners	Outperform	$32	+133.6%
Sep 09, 2026	Initiated	WWilliam Blair	Outperform
Aug 06, 2026	Initiated	TTD Cowen	Buy
Aug 05, 2026	Initiated	PPiper Sandler	Overweight	$42	+206.6%

Today 08:05AM	Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting (Business Wire) +42.71%
Oct-02-26 09:05AM	Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting (Business Wire)
Aug-06-26 09:48AM	Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls (The Fly)
Aug-05-26 09:40AM	Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls (The Fly) -16.15%
07:05AM	Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma (Business Wire)

Obsidian Therapeutics Inc. engages in developing cell and gene therapies, particularly for the treatment of solid tumors and cancer. The company was founded on September 29, 2015 and is headquartered in Malvern, PA.

Ph.D.Dr. Maria Fardis M.B.A.

M.S.Dr. Madan Jagasia M.D.

Chief Technical OfficerMr. Dana M. Alexander M.B.A.

M.S.Dr. Parameswaran Hari M.D.

Chief Financial OfficerMs. Julie B. Feder

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Obsidian Therapeutics Inc

Upgrade your Finviz experience